Rimonabant
General information:
| Withdrawn ID: | w72 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | A08AX01 |
| Molecular Formula: | C22H21Cl3N4O |
| Molweight: | 463.787 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First approved: | 2006 |
| First withdrawn: | 2008 |
| Last withdrawn: | 2008 |
| Reference: | https://www.ncbi.nlm.nih.gov/pubmed/25266008 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Rimonabant as primary suspect: | 1 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 1 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| WEIGHT INCREASED | 1 |
| VOMITING | 1 |
| RENAL PAIN | 1 |
| RENAL FAILURE | 1 |
| RECTAL HAEMORRHAGE | 1 |
| PYREXIA | 1 |
| NAUSEA | 1 |
| HYPERTENSION | 1 |
| HAEMORRHOIDS | 1 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 1 |
| FEAR OF EATING | 1 |
| DYSPEPSIA | 1 |
| CONSTIPATION | 1 |
| ATRIAL FIBRILLATION | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P02545 | 0.9 | Prelamin-A/C | LMNA_HUMAN |
| P21554 | 0.11 | Cannabinoid receptor 1 | CNR1_HUMAN |
| P34972 | 1.1 | Cannabinoid receptor 2 | CNR2_HUMAN |
| Q12809 | 2790 | Potassium voltage-gated channel subfamily H member 2 | KCNH2_HUMAN |
| Q9Y2T6 | 2010 | G-protein coupled receptor 55 | GPR55_HUMAN |
Toxicity information:
| Toxicity type: | neurological |
|---|
External links:
| ChEBML: | CHEMBL111 |
|---|---|
| DrugBank: | DB06155 |